Analyst Price Targets — ELVN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 9, 2026 10:05 am | Robert Burns | H.C. Wainwright | $65.00 | $50.80 | TheFly | Enliven price target raised to $65 from $56 at H.C. Wainwright |
| July 1, 2026 12:26 pm | — | Stifel Nicolaus | $80.00 | $50.68 | TheFly | Enliven price target raised to $80 from $60 at Stifel |
| June 8, 2026 8:10 pm | — | Stifel Nicolaus | $60.00 | $33.63 | TheFly | Enliven initiated with a Buy at Stifel |
| June 2, 2026 10:41 am | Salim Syed | Mizuho Securities | $62.00 | $37.51 | StreetInsider | Enliven Therapeutics (ELVN) PT Raised to $62 at Mizuho |
| May 12, 2026 12:28 am | — | Guggenheim | $80.00 | $39.59 | TheFly | Enliven initiated with a Buy at Guggenheim |
| May 8, 2026 12:00 pm | — | Goldman Sachs | $59.00 | $42.45 | TheFly | Enliven price target raised to $59 from $41 at Goldman Sachs |
| June 16, 2025 12:45 pm | Colleen Kusy | Robert W. Baird | $52.00 | $23.09 | TheFly | Enliven price target raised to $52 from $40 at Baird |
| March 21, 2025 10:18 am | — | H.C. Wainwright | $39.00 | $21.08 | TheFly | Enliven price target raised to $39 from $37 at H.C. Wainwright |
| November 15, 2024 12:17 pm | Colleen Kusy | Robert W. Baird | $40.00 | $24.05 | StreetInsider | Enliven Therapeutics (ELVN) PT Raised to $40 at Baird |
| September 23, 2024 11:00 am | Salim Syed | Mizuho Securities | $39.00 | $23.80 | StreetInsider | Mizuho Reiterates Outperform Rating on Enliven Therapeutics (ELVN) |
Latest News for ELVN
This Boulder biotech advancing cancer drugs saw a notable insider sale amid strong 1-year stock gains and early clinical progress.
Orbimed Advisors reported selling 860,123 shares of ELVN on June 22, 2026, generating a transaction value of approximately $39.0 million at an average price of $45.36 per share. This transaction represented 11.60% of Advisors Llc Orbimed's total indirect holdings, reducing indirect ownership from 7,415,225 to 6,555,102 shares.
BURLINGAME, Calif., June 15, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has closed its upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to…
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants PR Newswire
BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previously announced upsized underwritten public offering of 8,933,334 shares of its common stock at a price to the public of $37.50 per share…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ELVN.
U.S. House Trading
No House trades found for ELVN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.